Merck R&D Exec Jumps To US FDA As Office Of New Drugs Deputy Director
Peter Stein, a leader in diabetes drug development programs, joins FDA as a new administration is about to come in; he fills one of 676 CDER vacancies.
You may also be interested in...
Peter Stein Takes Short Path To Director Of US FDA Drug Office
An industry veteran, Stein has been with agency for only two years; Bob Temple becomes powerful OND "consultant."
US FDA Office Of New Drugs Likely To Be Headed By Deputy Director Stein
Peter Stein is a familiar face within OND and has been working alongside CDER Director Janet Woodcock on the proposed “modernization” of OND. As a previous recruit from outside FDA, Stein has had time to make the key connections and adjustments to working inside government.
FDA Scientists Give Leadership High Marks; Some Worry About Industry Influence
Union of Concerned Scientists' survey finds 65% of 354 respondents feel their direct supervisors back them on politically contentious positions; Commissioner Gottlieb gets glowing reviews.